Skip to content

Access MeMed BV Assay Clinical Study Collection Protocol - Infectious Adult and Pediatric Cohorts

Access MeMed BV Assay Clinical Study Collection Protocol - Infectious Adult and Pediatric Cohorts

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06379061
Enrollment
650
Registered
2024-04-23
Start date
2024-06-12
Completion date
2025-04-30
Last updated
2025-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection, Bacterial, Infection Viral

Brief summary

The purpose of the pivotal study is to collect blood specimens and clinical data from pediatric (\>90 days old) and adult (≥18 years old) patients presenting with signs and symptoms suggestive of acute bacterial or viral infection. These samples will be used to establish the diagnostic performance of MeMed BV™ for differentiating bacterial from viral infection using method comparison and/or method concordance.

Detailed description

The objective of this study is to collect blood specimens from pediatric (\>90 days old) and adult patients (≥18 years old) presenting with signs and symptoms suggestive of acute bacterial or viral infection from hospital, Emergency Department, or Urgent Care Centers for comparative testing on the Access 2 and DxI 9000 Immunoassay Analyzers.

Interventions

OTHERAdult and Pediatrics

This is an observational study. This protocol is for blood draw enrollment. These samples will be collected and binned by their results from the MeMed BV assay. Samples collected will be used for an analytical comparison study under a future testing protocol. These samples will be used to establish the diagnostic performance of MeMed BV test on BEC Access Immunoassay Systems for differentiating bacterial from viral infection.

Sponsors

MeMed Diagnostics Ltd.
CollaboratorINDUSTRY
Beckman Coulter, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
90 Days to 89 Years
Healthy volunteers
No

Inclusion criteria

* Over 90 days of age. * Clinical suspicion of acute bacterial or viral infection. * Temperature ≥ 37.8°C (100°F) (any body site, any measurement device, including self-reported) or tactile fever, either of them noted at least once within the last 7 days. * Current disease duration ≤ 7 days.

Exclusion criteria

* Previously enrolled * Insufficient sample volumes obtained * For the adult and pediatric populations, \< 1.2 mL serum volume * Sample handling errors * Another unrelated episode of febrile infection within the past 2 weeks * Suspicion and/or confirmed diagnosis of infectious gastroenteritis/ colitis. * ≥48 hours of oral antibiotic treatment * ≥12 hours of intravenous\\intramuscular antibiotic treatment * Human Immunodeficiency Viruses (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (self-declared or known from medical records) * A proven or suspected infection on presentation with Mycobacterial (e.g., Tuberculosis, MAC), parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus) pathogen * Active inflammatory disease (e.g., Inflammatory Bowel Disease \[IBD\], Systemic Lupus Erythematosus \[SLE\], Juvenile Idiopathic Arthritis \[JIA\], Rheumatoid Arthritis \[RA\], Kawasaki, other vasculitis) * Major trauma and\\or burns in the last 7 days. * Major surgery in the last 7 days * Congenital immune deficiency (CID) * Acquired immune deficiency\\modulation state including 1. Active malignancy treated within last 6 months 2. Current treatment with immune-suppressive or immune-modulating therapies, including without limitations: i. Administration of P.O.\\IV\\IM high dose steroids \>1mg/kg/day prednisone (or equivalent) at some point in the past 10 days or daily continuous use of steroids \> 0.25 mg/kg/day in the past 7 days ii. Monoclonal antibodies, anti-TNF agents iii. Intravenous immunoglobulin (IVIG) iv. Cyclosporine, Cyclophosphamide, Tacrolimus, Azathioprine, Methotrexate v. G/GM-CSF Interferons c. Post solid organ/bone marrow transplant patients d. Asplenia, sickle cell disease * Indwelling central venous catheter * Cystic Fibrosis * Pregnancy - self-reported or medically known * Other severe illnesses that affect life expectancy and quality of life such as: 1. Severe psychomotor retardation 2. Congenital metabolic disorder 3. End stage renal disease, advanced heart failure (NYHA 3/4), advanced COPD (GOLD 3/4)

Design outcomes

Primary

MeasureTime frameDescription
Blood Specimen CollectionLess or equal to seven daysCollect blood specimens across multiple age ranges presenting symptoms of acute or viral infection

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026